Addex Therapeutics vs CervoMed
ADXN and CRVO side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ADXN and CRVO compare
Addex Therapeutics grew revenue faster over the last twelve months (−92.6% versus −95.7% for CervoMed).
CervoMed scores higher on the StockData Score (5 against 0 for Addex Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ADXN | CRVO |
|---|---|---|
| Size and price | ||
| Market cap | – | $22.7M |
| Share price | $3.50 | $1.50 |
| Change, 1 year | −58.7% | −80.5% |
| Change, 5 years | −97.5% | −94.9% |
| Beta (5Y) | 1.95 | 3.41 |
| Employees | 3 | 15 |
| StockData Score | ||
| Total score | 0 | 5 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 0 | 4 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 68.5× |
| P/B | – | 1.0× |
| Growth | ||
| Revenue growth (TTM) | −92.6% (better) | −95.7% |
| Revenue growth, 5Y average | −61.6% | – |
| EPS growth (TTM) | −186% | – |
| Profitability | ||
| Operating margin | −9391% (better) | −9407% |
| Net margin | – | −9161% |
| FCF margin | −7244% | – |
| Return on equity | – | −108% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | −181.0× | – |
| Current ratio | 0.76 | – |
| Altman Z-score | – | −5.50 |
| Piotroski F-score | – | 1 |
| Dividends and buybacks | ||
| Shareholder yield | – | 0.00% |
| Ownership | ||
| Held by institutions | 0.00% | 11.6% |
| Held by insiders | 15.5% | 36.9% |
| Insider net buying, 12 months | – | $3.0M |
| Short interest, % of float | – | 12.7% |
Go deeper
- ADXN stock overview
- ADXN income statement
- ADXN valuation and score
- CRVO stock overview
- CRVO income statement
- CRVO valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.